Status: Recruiting
Osimertinib Plus Dalpiciclib in Patients With EGFR-mutant, CDK4/6 Pathway Aberrant, Advanced Non-small Cell Lung Cancer Following Acquired Resistance to Third-generation EGFR TKI: a Phase II Trial
This study is a prospective, single-arm, phase II trial. It is aimed to evaluate the efficacy and safety of the combination of osimertinib and dalpiciclib in patients with EGFR-mutant, CDK4/6 pathway aberrant, advanced NSCLC following acquired resistance to third-generation EGFR TKI.
Participants needed: 32
Trial details
Phase: Phase 2Age: 18-75Biological sex: AllType: InterventionalSponsor: Tianjin Medical University Cancer Institute and HospitalUpdated: Apr 16, 2024Locations: 1
Eligibility criteria
ECOG performance status 0 to 2 with a minimum life expectancy of 12 weeks [+6]
Prior treatment with any CDK4/6 inhibitor [+17]